Back to feature: Cancer Awareness Month

Cancer Statistics

  • Cancer is the leading cause of death in Canada, accounting for 30% of all deaths.
  • 2 in 5 Canadians will develop cancer in their lifetime.Footnote 1
  • 1 in 4 Canadians will die from cancer.Footnote 1
  • Each hour in Canada in 2016, an estimated 23 people were diagnosed with cancer. This is more than 500 per day.Footnote 1
  • Cancer costs the Canadian healthcare system an estimated $4.4 billion every year in direct and indirect costs, making it the 7th most costly illness or injury in Canada.Footnote 1
  • 60% of those diagnosed with cancer will live at least 5 years.Footnote 1

Gender Differences

  • In 2016, 102,900 Canadian men and 99,500 Canadian women were diagnosed with cancer.Footnote 1
  • Canadian females are more likely to develop breast cancer than any other type of cancer with 1 in 9 being diagnosed with it in their lifetime.Footnote 1
  • Canadian males are more likely to develop prostate cancer than any other type of cancer with 1 in 8 being diagnosed with it in their lifetime.Footnote 1

Cancer Immunotherapy Research

  • In 2015-2016, CIHR invested $156 million into cancer research, which was approximately 16% of CIHR total grants and awards investments.
  • CIHR has funded more than $68 million into cancer immunotherapy research, including more than $7 million in 2015-2016.
  • Immunotherapy can be used to treat many forms of cancer. A few examples could include:
    • Bladder cancer is the 5th most common cancer in Canada and accounts for 4% of all cancer cases.Footnote 1 Bladder cancer was one of the first cancers that immunotherapy was used to treat, and immunotherapy is currently making great advances in treating early-stage bladder cancer!Footnote 2
    • Almost 1,000,000 people worldwide are diagnosed with stomach cancer each year. Immunotherapy has great potential for treating advanced stomach cancers by using monoclonal antibodies.Footnote 3
    • Melanoma, the deadliest form of skin cancer, is showing great promise for treatment in current immunotherapy clinical trials!Footnote 4
Date modified: